

## Representative Life Sciences Deals

- Over \$25.0 Billion in Commitments to more than 700 Companies since 2003
- Total New Debt & Equity Commitments of \$3.92 Billion in 2025
- Total New Fundings of \$2.28 Billion in 2025
- Over 1,000 Co-investments with Different VC & PE Firms in the last 20+ Years
- Over 280 Companies completed IPO or M&A Events since Inception

 <p><b>\$150,000,000 Debt Commitment</b> <b>\$500,000 Equity Commitment</b></p> <p>Invested in 2013 - 2025 NASDAQ: QURE</p>	 <p><b>\$225,000,000 Debt Commitment</b></p> <p>Invested in 2025 NASDAQ: DYN</p>	 <p><b>\$175,000,000 Debt Commitment</b></p> <p>Invested in 2024 NASDAQ: IRON</p>	 <p><b>\$130,000,000 Debt Commitment</b></p> <p>Invested in 2025 NASDAQ: SVRA</p>
 <p><b>\$250,000,000 Debt Commitment</b> <b>\$2,250,000 Equity Commitment</b></p> <p>Invested in 2024, 2025 NYSE: RCUS</p>	 <p><b>\$45,000,000 Debt Commitment</b></p> <p>Invested in 2025 NASDAQ: ALT</p>	 <p><b>\$160,000,000 Debt Commitment</b></p> <p>Invested in 2019, 2022, 2023, 2026 NASDAQ: REPL</p>	 <p><b>\$90,000,000 Debt Commitment</b></p> <p>Invested in 2025 Private</p>
 <p><b>\$75,000,000 Debt Commitment</b></p> <p>Invested in 2024, 2025 Private</p>	 <p><b>\$300,000,000 Debt Commitment</b></p> <p>Invested in 2025 NASDAQ: MLTX</p>	 <p><b>\$250,000,000 Debt Commitment</b></p> <p>Invested in 2022, 2023, 2025 NASDAQ: VRDN</p>	 <p><b>\$130,000,000 Debt Commitment</b></p> <p>Invested in 2023, 2026 NASDAQ: CMPS</p>
 <p><b>\$100,000,000 Debt Commitment</b></p> <p>Invested 2022 NASDAQ: KURA</p>	 <p><b>\$300,000,000 Debt Commitment, Syndicated Royalty Commitment</b></p> <p>Invested in 2021, 2022, 2023 NASDAQ: PHAT</p>	 <p><b>\$65,000,000 Debt Commitment</b></p> <p>Invested in 2023, 2024, 2025 NYSEAM: SENS</p>	 <p><b>\$40,000,000 Debt Commitment</b></p> <p>Invested in 2025 Private</p>

Note: Commitments represent total amount of committed capital on the facility, which in select cases includes syndicated amount with partners.

 <p><b>Madrigal</b> Pharmaceuticals</p> <p>\$190,000,000 <b>Debt Commitment</b> \$1,200,000 <b>Equity Commitment</b></p> <p>Invested in 2022, 2023 NASDAQ: MDGL</p>	 <p><b>HERON</b> THERAPEUTICS</p> <p>\$150,000,000 <b>Debt Commitment</b> \$500,000 <b>Equity Commitment</b></p> <p>Invested in 2023, 2025 NASDAQ: HRTX</p>	 <p><b>Orchestra</b> BioMed</p> <p>\$30,000,000 <b>Debt Commitment</b></p> <p>Invested in 2024 NASDAQ: OBIO</p>	 <p><b>SIGHT</b> SCIENCES</p> <p>\$65,000,000 <b>Debt Commitment</b></p> <p>Invested in 2024 NASDAQ: SGHT</p>
 <p><b>enGene</b></p> <p>\$125,000,000 <b>Debt Commitment</b></p> <p>Invested in 2021, 2023, 2026 NASDAQ: ENGN</p>	 <p><b>braeburn</b></p> <p>\$100,000,000 <b>Debt Commitment</b></p> <p>Invested in 2023 Private</p>	 <p><b>axsome</b></p> <p>\$275,000,000 <b>Debt Commitment</b> \$5,000,000 <b>Equity Commitment</b></p> <p>Invested in 2020, 2021, 2022, 2023 NASDAQ: AXSM</p>	 <p><b>X4</b> PHARMACEUTICALS</p> <p>\$82,500,000 <b>Debt Commitment</b> \$3,500,000 <b>Equity Commitment</b></p> <p>Invested in 2018, 2019, 2020, 2022, 2023 NASDAQ: XFOR</p>
 <p><b>SynOx</b> Therapeutics</p> <p>\$25,000,000 <b>Debt Commitment</b></p> <p>Invested in 2024 Private</p>	 <p><b>akero</b></p> <p>\$100,000,000 <b>Debt Commitment</b> \$2,000,000 <b>Equity Commitment</b></p> <p>Invested in 2022, 2024 Acquired by Novo Nordisk</p>	 <p><b>TG Therapeutics</b></p> <p>\$140,000,000 <b>Debt Commitment</b></p> <p>Invested in 2019, 2021, 2023 NASDAQ: TGTX</p>	 <p><b>alector</b></p> <p>\$25,000,000 <b>Debt Commitment</b></p> <p>Invested in 2024 NASDAQ: ALEC</p>
 <p><b>AVEO</b> ONCOLOGY</p> <p>\$45,000,000 <b>Debt Commitment</b> ~\$500,000 <b>Equity Commitment</b></p> <p>Invested 2006 - 2022 Acquired by LG Chem</p>	 <p><b>proventionbio</b></p> <p>\$100,000,000 <b>Debt Commitment</b></p> <p>Invested in 2022, 2023 Acquired by Sanofi</p>	 <p><b>IVERIC</b> BIO</p> <p>\$200,000,000 <b>Debt Commitment</b></p> <p>Invested in 2022 Acquired by Astellas</p>	 <p><b>Verona Pharma</b></p> <p>\$300,000,000 <b>Debt Commitment</b></p> <p>Invested in 2023 Acquired by Merck</p>

Note: Commitments represent total amount of committed capital on the facility, which in select cases includes syndicated amount with partners.

### Boston Office

**R. Bryan Jadot**  
Sr. Managing Director  
and Group Head  
617.314.9981  
[bjadot@htgc.com](mailto:bjadot@htgc.com)

**Jeff Ralto**  
Managing Director  
857.202.5387  
[jralto@htgc.com](mailto:jralto@htgc.com)

**Michael McMahon**  
Managing Director  
857.206.8964  
[mmcmahon@htgc.com](mailto:mmcmahon@htgc.com)

**Michael Dutra**  
Sr. Managing Director  
& Sr. Investment Officer  
617.314.9989  
[mdutra@htgc.com](mailto:mdutra@htgc.com)

### New York Office

**John Miotti**  
Principal  
347.329.3299  
[jmiotti@htgc.com](mailto:jmiotti@htgc.com)

### San Mateo Office

**Cristy Barnes**  
Managing Director  
650.600.5432  
[cbarnes@htgc.com](mailto:cbarnes@htgc.com)

**Briana Gironda**  
Principal  
650.600.5421  
[bgironda@htgc.com](mailto:bgironda@htgc.com)

### San Diego Office

**Lake McGuire**  
Managing Director  
517.304.0382  
[lmcguire@htgc.com](mailto:lmcguire@htgc.com)

### Denver Office

**Tom Hertzberg**  
Managing Director  
719.203.7709  
[thertzberg@htgc.com](mailto:thertzberg@htgc.com)

**Brian Powers**  
Managing Director  
719.203.7728  
[bpowers@htgc.com](mailto:bpowers@htgc.com)

### DC/MD/VA Region

**Adam Soller**  
Managing Director  
571.309.1347  
[asoller@htgc.com](mailto:asoller@htgc.com)